Avalon GloboCare Announces Commercial Launch of KetoAir Breathalyzer at the KetoCon Austin 2023 Conference
FREEHOLD, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative cell-based technology, cellular therapy and precision diagnostics, today announced the commercial launch of the KetoAir™ breathalyzer device and related accessories at the KetoCon Austin 2023 conference, which is being held on April 21-23, 2023 in Austin, Texas. Avalon will showcase the KetoAir™ in booth #523.
KetoAir™ functions as a companion diagnostic and monitoring device, combined with an artificial intelligence (AI) nutritionist consultation for ketogenic dietary management (United States FDA registration number: 862.1820).
“We recently announced that we have partnered with Qi Diagnostics to exclusively distribute the KetoAir™ in North America, South America, the U.K. and the EU. We are excited to now showcase the device at the KetoCon conference, as this represents the official commercial launch of KetoAir™ in North America,” stated David Jin, M.D., Ph.D., President and Chief Executive Officer of Avalon GloboCare. “Initially, we will target the diabetes reversal and obesity management markets, since the ketogenic diet is an effective treatment option for both diabetes and weight management.”
“KetoAir™ is the first breathalyzer on the market that uses an AI nutritionist bundled with the nanosensor-based breathalyzer for ketogenic health management. The KetoAir™ breathalyzer measures the keto status and logs the diet records in the KetoAir app. At the same time, the AI nutritionist analyzes the dietary plan and acts as a companion consultant by providing personalized nutritional and exercise recommendations to help achieve the person’s ultimate health goal. We encourage everyone to stop by our booth and try out KetoAir™ for themselves,” concluded Dr. Jin.
About KetoCon
KetoCon is a conference series owned and organized by Q1 Productions, LLC. KetoCon is the largest conference of its kind, presenting the benefits of utilizing ketosis, biohacking, sleep hygiene, and various nutritional protocols to improve metabolic health. For more information, please visit www.ketocon.org/ketocon-2023.
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a clinical-stage biotechnology company dedicated to developing and delivering innovative, transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients’ growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press release may constitute “forward-looking statements.” Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact, including statements regarding the ability to enter into a definitive agreement, the commercialization of KetoAir. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (http://www.sec.gov). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this press release represent the Company's views as of the date of this press release and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of the press release.
Contact Information:
Avalon GloboCare Corp.
4400 Route 9, Suite 3100
Freehold, NJ 07728
PR@Avalon-GloboCare.com
Investor Relations:
Crescendo Communications, LLC
Tel: (212) 671-1020 Ext. 304
albt@crescendo-ir.com
Released April 17, 2023